Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
Inflammatory arthritis
•
Orthopedics
What is your approach to assessing inflammatory arthritis flares in joints that have been replaced (such as knees)?
Related Questions
When considering a biologic for seropositive RA after failure of methotrexate or triple therapy, do you consider using abatacept as a first line biologic or would prefer choosing TNFi?
Do you combine methotrexate and leflunomide for the treatment of RA?
What is your approach to work up for patients referred for early onset osteoarthritis?
Are there concerns with combining anti-IL5 biologics (mepolizumab or benralizumab) for severe asthma with other biologics for RA (e.g. TNFi)?
How do you approach management of DMARDs and biologics in a patient with active RA, but frequent recurrent simple UTIs?
How do you approach treatment of a patient with active RA and a history of Lynch Syndrome?
Does the presence of calcified granulomas on chest imaging influence your choice of biologic for treatment of psoriatic arthritis (or rheumatoid arthritis)?
Are there any immunosuppressive agents that have been shown to have utility in concurrent idiopathic anaphylaxis?
What is your approach to monitoring patients referred for high titer +RF and +CCP but without active symptoms of inflammatory arthritis?
How do you approach treating a patient with RA and cirrhosis who did not respond to csDMARDs?
